Goldman Sachs raises target for Sonova stock to CHF 315.00

Published on 10/08/2026 at 18:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman expects 9.00 percent revenue growth versus 6.20 percent consensus. Sonova stock stood at EUR 273.25 on October 8, 2026.

Key points in brief

Goldman Sachs upgraded Sonova to Buy and raised its price target from CHF 230.00 to CHF 315.00 on October 8, 2026.
Goldman expects constant-currency revenue growth of 9.00 percent in the first half of fiscal 2027 versus 6.20 percent consensus.
Sonova stock was quoted at EUR 273.25 at Lang & Schwarz on October 8, 2026 in after-hours trading.
Sonova is listed on the SIX Swiss Exchange under ticker SOON and operates in healthcare and medical devices.

A soft watercolor illustration of a Swiss alpine lake surrounded by snow-capped mountains with birds in flight reflected on the calm water surface, gentle concentric sound wave ripples radiating across the lake as stylized acoustic waves, rendered in past — Sonova CH0012549785: Aquarell eines Schweizer Sees mit Vögeln und stilisierten Schallwellen in Pastelltönen, Illustration mit AI erstellt.

Sonova stock (ISIN CH0012549785) was quoted at EUR 273.25 at Lang & Schwarz on October 8, 2026 in after-hours trading. On the same date, Yahoo Finance reported that Goldman Sachs upgraded Sonova from Neutral to Buy and raised its price target from CHF 230.00 to CHF 315.00.

Three events shape the story

On May 18, 2026, Sonova reported fiscal 2025/26 sales of CHF 3,605.9 million, up 5.9 percent in local currencies, in its annual financial report. The report also showed normalized EBITA of CHF 811.2 million, up 17.3 percent in local currencies, giving the later analyst upgrade a stronger earnings backdrop.

On August 24, 2026, Sonova announced the Phonak EON portfolio, including third-generation proprietary real-time artificial intelligence hearing aids. On October 8, 2026, Goldman Sachs followed with the CHF 315.00 target and Buy rating.

What does growth mean for margins?

Investing.com reported that Goldman expects constant-currency revenue growth of 9.00 percent in the first half of fiscal 2027, compared with Visible Alpha consensus of 6.20 percent. Goldman also forecasts adjusted EBIT growth of 12.60 percent versus 6.50 percent consensus, a quantified gap that places operating leverage at the center of the investment case.

The annual report supplies a counterweight. Cochlear Implants sales fell 11.1 percent in local currencies to CHF 252.1 million in fiscal 2025/26, while Hearing Instruments sales rose 7.5 percent to CHF 3,353.8 million. Sonova therefore enters the next reporting period with strong hearing-aid momentum but a weaker implant division.

Upcoming results have a fixed date

Sonova lists November 17, 2026 for publication of its half-year results as of September 30, 2026 and May 12, 2027 for publication of full-year results as of March 31, 2027. Those dates will test whether the first-half growth profile approaches Goldman's 9.00 percent forecast.

Sonova stock and the latest quote

Sonova was quoted at EUR 273.25 at Lang & Schwarz on October 8, 2026 in after-hours trading. Its primary listing is on the SIX Swiss Exchange, where the company trades under ticker SOON and reports in Swiss francs.

The further course of trading is shown by the continuously updated real-time quote of Sonova stock.